{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:10:56Z","timestamp":1771233056102,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.carrev.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T05:26:29Z","timestamp":1706419589000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design"],"prefix":"10.1016","volume":"63","author":[{"given":"Andrea","family":"Teira Calder\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Chiarito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio Amat","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Vaquerizo Montilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Jurado Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Pulido Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor M.","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"D\u00edez-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Sanz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.carrev.2024.01.013_bb0005","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions","volume":"21","author":"Lip","year":"2019","journal-title":"EP Europace"},{"issue":"16","key":"10.1016\/j.carrev.2024.01.013_bb0010","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2024.01.013_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.08.089","article-title":"Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention","volume":"223","author":"Kowalewski","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2024.01.013_bb0020","doi-asserted-by":"crossref","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, andomized, controlled trial. The Lancet 2013;381(9872):1107\u20131115. Doi:https:\/\/doi.org\/10.1016\/S0140-6736(12)62177-1.","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"10.1016\/j.carrev.2024.01.013_bb0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2015.01.056","article-title":"Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study","volume":"183","author":"Kiviniemi","year":"2015","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.carrev.2024.01.013_bb0030","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ageing\/afx073","article-title":"Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: a case report","volume":"46","author":"Nagasayi","year":"2017","journal-title":"Age Ageing"},{"key":"10.1016\/j.carrev.2024.01.013_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijcard.2016.03.148","article-title":"Rebound thrombosis within 24 hours after interruption of therapy with rivaroxaban","volume":"212","author":"Bakhit","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9129","key":"10.1016\/j.carrev.2024.01.013_bb0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(97)11128-X","article-title":"Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)","volume":"352","author":"Serruys","year":"1998","journal-title":"The Lancet"},{"issue":"19","key":"10.1016\/j.carrev.2024.01.013_bb0045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"31","key":"10.1016\/j.carrev.2024.01.013_bb0050","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","year":"2019","journal-title":"Eur Heart J"},{"issue":"9986","key":"10.1016\/j.carrev.2024.01.013_bb0055","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.carrev.2024.01.013_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5603\/CJ.a2021.0036","volume":"28","year":"2021","journal-title":"Cardiol J"},{"issue":"24","key":"10.1016\/j.carrev.2024.01.013_bb0065","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.carrev.2024.01.013_bb0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.carrev.2024.01.013_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.carrev.2024.01.013_bb0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5551\/jat.60129","article-title":"Prognostic and practical validation of ESC\/EACTS high ischemic risk definition on long-term thrombotic and bleeding events in contemporary PCI patients","volume":"29","author":"Wang","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.carrev.2024.01.013_bb0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12872-020-01600-3","article-title":"Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.carrev.2024.01.013_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2024.01.013_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"issue":"18","key":"10.1016\/j.carrev.2024.01.013_bb0100","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/jcm12185955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.carrev.2024.01.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001026","article-title":"Performing diagnostic radial access coronary angiography on uninterrupted direct oral anticoagulant therapy: a prospective analysis","volume":"6","author":"Chongprasertpon","year":"2019","journal-title":"Open Heart"},{"issue":"2","key":"10.1016\/j.carrev.2024.01.013_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009949","article-title":"Percutaneous coronary intervention without interruption of oral anticoagulation","volume":"14","author":"C\u00f3rdoba-Soriano","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.carrev.2024.01.013_bb0115","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcin.2021.01.022","article-title":"Uninterrupted oral anticoagulant therapy in patients undergoing unplanned percutaneous coronary intervention","volume":"14","author":"Venetsanos","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2024.01.013_bb0120","first-page":"9","article-title":"Impact of non-vitamin K antagonist oral anticoagulant withdrawal on stroke outcomes","author":"Park","year":"2018","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.carrev.2024.01.013_bb0125","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 RS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.carrev.2024.01.013_bb0130","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.carrev.2024.01.013_bb0135","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.carrev.2024.01.013_bb0140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2024.01.013_bb0145","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2024.01.013_bb0150","doi-asserted-by":"crossref","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509\u20131524. Doi: https:\/\/doi.org\/10.1056\/NEJMoa1817083 Crossref. PubMed.","DOI":"10.1056\/NEJMoa1817083"},{"key":"10.1016\/j.carrev.2024.01.013_bb0155","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomized, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838924000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838924000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T03:51:49Z","timestamp":1716436309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838924000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"alternative-id":["S1553838924000149"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2024.01.013","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}